Submitted: 11 December 2025 You are already at the latest version Drug discovery faces significant obstacles posed by unpredictable pharmacokinetic and safety properties, necessitating a complex, multiparameter optimization process. ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) issues remain the primary reason for failure in drug development, with over 90% of discovery compounds failing basic ADME standards and unexpected ADMET problems causing around 30% of clinical setbacks.
